Sanofi (NASDAQ:SNY) Holdings Decreased by Balyasny Asset Management L.P.

Balyasny Asset Management L.P. decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 89.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,094 shares of the company’s stock after selling 600,655 shares during the quarter. Balyasny Asset Management L.P.’s holdings in Sanofi were worth $3,429,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC grew its stake in Sanofi by 107.5% in the third quarter. Barclays PLC now owns 639,772 shares of the company’s stock valued at $36,869,000 after purchasing an additional 331,445 shares in the last quarter. ORG Partners LLC grew its stake in Sanofi by 17.7% in the fourth quarter. ORG Partners LLC now owns 1,681 shares of the company’s stock valued at $81,000 after purchasing an additional 253 shares in the last quarter. Thomasville National Bank grew its stake in Sanofi by 1.6% in the fourth quarter. Thomasville National Bank now owns 80,101 shares of the company’s stock valued at $3,863,000 after purchasing an additional 1,265 shares in the last quarter. Cooper Financial Group grew its stake in Sanofi by 2.1% in the fourth quarter. Cooper Financial Group now owns 13,332 shares of the company’s stock valued at $643,000 after purchasing an additional 274 shares in the last quarter. Finally, Forza Wealth Management LLC grew its stake in Sanofi by 147.3% in the fourth quarter. Forza Wealth Management LLC now owns 9,235 shares of the company’s stock valued at $445,000 after purchasing an additional 5,500 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Stock Down 4.1%

SNY opened at $49.98 on Monday. The business has a 50 day moving average price of $54.22 and a 200 day moving average price of $52.00. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The firm has a market cap of $126.26 billion, a P/E ratio of 20.07, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm had revenue of $10.41 billion during the quarter, compared to analyst estimates of $9.79 billion. During the same period in the previous year, the company earned $1.78 EPS. The company’s revenue for the quarter was down 11.0% on a year-over-year basis. Research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be given a $2.0369 dividend. This is an increase from Sanofi’s previous annual dividend of $1.48. This represents a yield of 3.1%. The ex-dividend date of this dividend is Friday, May 9th. Sanofi’s payout ratio is currently 57.14%.

Analyst Ratings Changes

A number of research analysts have commented on the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. BNP Paribas began coverage on Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price on the stock. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Finally, The Goldman Sachs Group began coverage on Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price for the company. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and a consensus target price of $63.33.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.